MISSION Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced
Company Description At Sobi, each person brings their unique talents to work as a team and make a difference. We are dedicated to developing and delivering innovative therapies to improve the lives of people who live
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Role Summary The Regional Category Manager is responsible for executing procurement strategies with 3rd party suppliers in support of Fresenius Medical Care’s One Procurement strategy. Responsible for category management, strategic sourcing, supplier negotiations, contracting, and ongoing supplier
Overview Bruker enables scientists and engineers to make groundbreaking post-genomic discoveries and develop new applications that improve people’s quality of life. Bruker’s high-performance scientific instruments and high-quality analytical and diagnostic solutions allow scientists to explore life
MISSION Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced
Projekt: For our client, a major pharmaceutical company based in Basel, we are looking for a Quality System Engineer- Medical Devices Background: Digital Health Technologies (DHTs), including those with medical device capabilities, are critical for enhancing
The Botnar Institute of Immune Engineering (BIIE) is a new interdisciplinary research institute dedicated to innovation in immune engineering. Founded in 2024 through a generous endowment from Fondation Botnar, the BIIE supports scientists in taking on
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Digital Health Technologies (DHTs), including those with medical device capabilities, are critical for enhancing patient value. To address the varying measurement needs across our clinical trials, we partner with multiple third-party DHT manufacturers. While DHTs are